Kerr Douglas 4

What Happened Kerr Douglas, Chief Medical Officer of Dyne Therapeutics (DYN), received equity awards on February 12, 2026: 85,000 restricted stock units (RSUs) and a derivative award of 130,000 shares (stock option). Both awards are recorded at $0.00 acquisition price on the Form 4 (typical for compensation grants).

Key Details

• Transaction date: February 12, 2026; Form filed February 17, 2026 (appears to be outside the usual two-business-day Form 4 window).
• Awards: 85,000 RSUs (F1) and a 130,000-share option/derivative (F3).
• Vesting: RSUs vest in equal quarterly installments over four years, with the first vesting on May 12, 2026 (F1). The option vests in equal monthly installments over four years through February 12, 2030 (F3).
• Ownership note: The filing indicates 156,625 unvested RSUs are included in reported ownership (F2).
• Price/value shown: both entries reported at $0.00 (award/grant); the Form does not show proceeds from any sale.

Context These entries are compensation awards (not open-market purchases or sales). RSUs convert to shares only as they vest; options require vesting and exercise to generate shares. Such grants are commonly part of executive compensation and do not by themselves indicate buying or selling sentiment.